Showing 2231-2240 of 3139 results for "".
- Are COVID-19 Vaccines Safe for Filler Patients?https://modernaesthetics.com/news/facial-fillers-and-covid-19-vaccines-is-there-a-risk-for-adverse-reactions/2473036/Three patients with dermal fillers have had adverse reactions to the Moderna COVID-19 vaccine, according to the Aesthetic Society. The FDA intends to note this in its prescribing information. There have been no reported cases in patients receiving the Pfizer COVID-19 vaccine.
- Revance Therapeutics and Ajinomoto Bio-Pharma Services Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injectionhttps://modernaesthetics.com/news/revance-therapeutics-and-ajinomoto-bio-pharma-services-announce-manufacturing-agreement-for-supply-of-daxibotulinumtoxina-for-injection/2473035/Ajinomoto Bio-Pharma Services will serve as a supply source and provide manufacturing for Revance Therapeutics, Inc.’s DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection is currently under Biologics License Application (BLA) review.
- Done Deal: DermOQ Oxygen Lab Acquires ECHO2 Plus Oxygen Facial Treatment Product Line from Skin Products, Inc.https://modernaesthetics.com/news/done-deal-dermoq-oxygen-lab-acquires-echo2-plus-oxygen-facial-treatment-product-line-from-skin-products-inc/2473034/DermOQ Oxygen Lab closed their acquisition of ECHO2 Plus Oxyceuticals oxygen facial treatment product line from Skin Products, Inc. for an undisclosed amount. "ECHO2 Plus is a 45-minute facial treatment offered at physician's offices, spas, hotels and corporate custom
- Phase 2 DaxibotulinumtoxinA Data Highlight Efficacy for Upper Facial Lineshttps://modernaesthetics.com/news/phase-2-daxibotulinumtoxina-data-highlight-efficacy-for-upper-facial-lines/2473032/Topline efficacy and safety results from the phase 2 multicenter, open-label study of Revance's investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, show high levels of patient satisfaction. The 36-week study enrolled 48
- HydraFacial To Go Public After SPAC Dealhttps://modernaesthetics.com/news/hydrafacial-to-go-public-after-spac-deal/2473028/The HydraFacialCompany and Vesper Healthcare, a special purpose acquisition company (SPAC) co-founded by Brent Saunders, former CEO of Allergan, have entered into a definitive merger agreement. Under the terms of the agreement, HydraFacial and Vesper Healthcare will combine, and HydraFa
- Crown Aesthetics’ SkinPen Precision Scores Class IIa CE Certification from the British Standards Institutionhttps://modernaesthetics.com/news/crown-aesthetics-skinpen-precision-scores-class-iia-ce-certification-from-the-british-standards-institution/2473019/The British Standards Institution (BSI) granted a Class IIa CE Certification mark to Crown Aesthetics’ SkinPen Precision. The certification confirms SkinPen as a treatment to improve the appearance of facial acne scars in adults aged 22 years or older and to improve the appe
- Promising Results from Dysport Dose Escalation Studyhttps://modernaesthetics.com/news/promising-results-from-dysport-dose-escalation-study/2473018/Top-line results from a Phase 2 dose escalation study show that significantly more subjects treated with Dysport® at all four doses achieved a composite two grade improvement responder rate than those treated with placebo at one month. The study accessed the duration of ef
- Soliton Appoints Aesthetic Executive Veteran Brad Hauser as President and CEO in Preparation for Commercial Launchhttps://modernaesthetics.com/news/soliton-appoints-aesthetic-executive-veteran-brad-hauser-as-president-and-ceo-in-preparation-for-commercial-launch/2473013/Soliton, Inc., has named Brad A. Hauser as President and Chief Executive Officer of Soliton. He most recently served as Vice President, R&D and General Manager for CoolSculpting at Allergan Aesthetics, an AbbVie Company, since Allergan's
- Significant Growth Predicted for Vaginal Rejuvenation Markethttps://modernaesthetics.com/news/significant-growth-predicted-for-vaginal-rejuvenation-market/2473010/The global Vaginal Rejuvenation Market is projected to grow at over 33.7% between 2020 and 2026 from its estimated USD 1 billion value in 2019. A recent study from market research firm Global Market Insights,the growth will be driven in part by the prevalence of stress ur
- The HydraFacial Company and Circadia Expand Partnershiphttps://modernaesthetics.com/news/the-hydrafacial-company-and-circadia-expand-partnership/2473009/The HydraFacial Company is extending their partnership with Circadia to offer the Chrono-Peptide Booster and ProTec Plus Booster to HydraFacial providers in more than 40 countries. "The Circadia boosters for HydraFacial are already loved by providers and consume